EED226 is primarily used in research settings as a potent and selective inhibitor of the embryonic ectoderm development (EED) protein, a core component of the polycomb repressive complex 2 (PRC2). By targeting the EED subunit, EED226 disrupts PRC2-mediated methylation of histone H3 at lysine 27 (H3K27me3), a key epigenetic mark associated with gene silencing. This inhibition leads to the reactivation of tumor suppressor genes and other regulatory genes silenced in certain cancers, making EED226 a valuable tool in oncology research, particularly in studying hematological malignancies and solid tumors. Its application extends to investigating epigenetic mechanisms in cell differentiation, development, and disease progression. Due to its high selectivity and ability to overcome resistance mutations seen with other PRC2 inhibitors, EED226 supports the development of novel epigenetic therapies and serves as a reference compound in drug discovery programs focused on chromatin-modifying enzymes.